The ROC analysis showed that ANGPTL4 could be used to predict lymph node metastasis patients with the cutoff 0.5399 AU, sensitivity of 71.4% and specificity of 70.8% (AUC = 0.691, YI = 0.423, p = 0.01). This evidence concerns the gene ANGPTL4 and metastatic malignant neoplasm in the lymph nodes.